Managing catastrophic medical claims -prescription drug trends

<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
  <record>
    <leader>00000cab a2200000   4500</leader>
    <controlfield tag="001">MAP20190020879</controlfield>
    <controlfield tag="003">MAP</controlfield>
    <controlfield tag="005">20190709110311.0</controlfield>
    <controlfield tag="008">190705e20190107usa|||p      |0|||b|eng d</controlfield>
    <datafield tag="040" ind1=" " ind2=" ">
      <subfield code="a">MAP</subfield>
      <subfield code="b">spa</subfield>
      <subfield code="d">MAP</subfield>
    </datafield>
    <datafield tag="084" ind1=" " ind2=" ">
      <subfield code="a">7</subfield>
    </datafield>
    <datafield tag="100" ind1="1" ind2=" ">
      <subfield code="0">MAPA20190009331</subfield>
      <subfield code="a">Troutman, Mark</subfield>
    </datafield>
    <datafield tag="245" ind1="0" ind2="0">
      <subfield code="a">Managing catastrophic medical claims -prescription drug trends</subfield>
      <subfield code="c"> Mark Troutman, Larry P. Jackson</subfield>
    </datafield>
    <datafield tag="300" ind1=" " ind2=" ">
      <subfield code="a">5 p. </subfield>
    </datafield>
    <datafield tag="520" ind1=" " ind2=" ">
      <subfield code="a">The major impact trend on catastrophic medical claims is specialty pharmacy developments in biosimilars, orphan drugs, and breakthrough therapies. This increasing pipeline of new specialty drugs and targeted therapies results from several market trends. Pharmaceutical manufacturers continue their direct-to-consumer advertising to increase consumer awareness. Increased utilization naturally occurs due to the aging population and trend toward outpatient health care, as well as new and more aggressive drug treatment plans. This situation creates a pushpull conflict between supplier and payer as suppliers push for solutions at highest cost to increase margin and payers push for solutions and lowest cost to increase bottom line.</subfield>
    </datafield>
    <datafield tag="650" ind1=" " ind2="4">
      <subfield code="0">MAPA20080567118</subfield>
      <subfield code="a">Reclamaciones</subfield>
    </datafield>
    <datafield tag="650" ind1=" " ind2="4">
      <subfield code="0">MAPA20080606633</subfield>
      <subfield code="a">Industria farmacéutica</subfield>
    </datafield>
    <datafield tag="700" ind1="1" ind2=" ">
      <subfield code="0">MAPA20080195519</subfield>
      <subfield code="a">Jackson, Larry P.</subfield>
    </datafield>
    <datafield tag="773" ind1="0" ind2=" ">
      <subfield code="w">MAP20190020794</subfield>
      <subfield code="t">Contingencies : American Academy of Actuaries</subfield>
      <subfield code="d">Washington : American Academy of Actuaries, 2019-</subfield>
      <subfield code="g">07/01/2019 Año 2019 - January-February , p. 38-42</subfield>
    </datafield>
  </record>
</collection>